Literature DB >> 22410961

Faecal calprotectin levels before and after weight loss in obese and overweight subjects.

P Kant1, R Fazakerley, M A Hull.   

Abstract

Faecal calprotectin (FCP) is a non-invasive biomarker of intestinal inflammation, levels of which are reported to be elevated in individuals with increased body mass index (BMI). We investigated whether weight loss (WL), induced by dietary and behavioural change in a community weight loss programme (Slimming World), was associated with a reduction in FCP in a longitudinal cohort study. We obtained paired stool samples at the start and 11-15 weeks into the weight loss programme in 40 individuals with a BMI >25 kg m(-2) and no known colorectal or systemic inflammatory condition. Eight of 40 (20%) 'healthy' participants had a baseline FCP greater than 50 μg g(-1) (the accepted adult cutoff value for FCP), termed FCP(high). Although the degree (%) of WL was similar (5.1 FCP(high) versus 6.1 FCP(normal); P=0.63), only FCP(high) individuals, but not FCP(normal) participants, demonstrated a reduction in FCP level (median 0.3-fold versus 1.0-fold (that is, no change) during the study period (P=0.065). A large prospective cohort study of FCP(high) and FCP(normal) obese individuals is now required to determine the relationship between local mucosal inflammation and the systemic inflammatory state associated with obesity, as well as understand the relationship between FCP levels, WL and future risk of colorectal neoplasia.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22410961     DOI: 10.1038/ijo.2012.38

Source DB:  PubMed          Journal:  Int J Obes (Lond)        ISSN: 0307-0565            Impact factor:   5.095


  15 in total

Review 1.  The role of obesity in oesophageal cancer development.

Authors:  Elizabeth Long; Ian L P Beales
Journal:  Therap Adv Gastroenterol       Date:  2014-11       Impact factor: 4.409

Review 2.  What does irritable bowel syndrome share with non-alcoholic fatty liver disease?

Authors:  Antonella Scalera; Matteo Nicola Dario Di Minno; Giovanni Tarantino
Journal:  World J Gastroenterol       Date:  2013-09-07       Impact factor: 5.742

3.  Paving the way towards a weight-loss intervention study in obese patients with inflammatory bowel disease.

Authors:  Julien Kirchgesner
Journal:  United European Gastroenterol J       Date:  2020-10-12       Impact factor: 4.623

4.  Effects of obesity and weight loss on mitochondrial structure and function and implications for colorectal cancer risk.

Authors:  S P Breininger; F C Malcomson; S Afshar; D M Turnbull; L Greaves; J C Mathers
Journal:  Proc Nutr Soc       Date:  2019-03-22       Impact factor: 6.297

5.  Faecal Inflammatory Biomarkers and Gastrointestinal Symptoms after Bariatric Surgery: A Longitudinal Study.

Authors:  Floris Westerink; Inge Huibregtse; Marieke De Hoog; Sjoerd Bruin; Eelco Meesters; Desiderius Brandjes; Victor Gerdes
Journal:  Inflamm Intest Dis       Date:  2021-04-14

Review 6.  Pathophysiological mechanisms linking obesity and esophageal adenocarcinoma.

Authors:  Leo Alexandre; Elizabeth Long; Ian Lp Beales
Journal:  World J Gastrointest Pathophysiol       Date:  2014-11-15

7.  International consensus on methodological issues in standardization of fecal calprotectin measurement in inflammatory bowel diseases.

Authors:  Ferdinando D'Amico; David T Rubin; Paulo Gustavo Kotze; Fernando Magro; Britta Siegmund; Taku Kobayashi; Pablo A Olivera; Peter Bossuyt; Lieven Pouillon; Edouard Louis; Eugeni Domènech; Subrata Ghosh; Silvio Danese; Laurent Peyrin-Biroulet
Journal:  United European Gastroenterol J       Date:  2021-05-07       Impact factor: 4.623

8.  Association of clinical characteristics and lifestyle factors with fecal S100/calgranulin concentrations in healthy dogs.

Authors:  Romy M Heilmann; Melissa M Guard; Linda Toresson; Stefan Unterer; Aurélien Grellet; Niels Grützner; Jan S Suchodolski; Joerg M Steiner
Journal:  Vet Med Sci       Date:  2021-03-10

Review 9.  Faecal calprotectin: factors affecting levels and its potential role as a surrogate marker for risk of development of Crohn's Disease.

Authors:  Michael A Mendall; Derek Chan; Roshani Patel; Devinder Kumar
Journal:  BMC Gastroenterol       Date:  2016-10-07       Impact factor: 3.067

10.  Fecal Calprotectin, Elastase, and Alpha-1-Antitrypsin Levels After Roux-en-Y Gastric Bypass; Calprotectin Is Significantly Elevated in the Majority of Patients.

Authors:  Thomas C C Boerlage; Floris Westerink; Dennis C W Poland; Inge L Huibregtse; Yair I Z Acherman; Victor E A Gerdes
Journal:  Obes Surg       Date:  2016-12       Impact factor: 4.129

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.